Skip to main navigation
Skip to search
Skip to main content
Mayo Clinic Home
Search content at Mayo Clinic
Home
Profiles
Departments/Divisions
Grants
Research output
Prizes
Review: Medical treatment of advanced colorectal cancer in 2009
Axel Grothey
Medical Oncology
Research output
:
Contribution to journal
›
Review article
›
peer-review
5
Link opens in a new tab
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Review: Medical treatment of advanced colorectal cancer in 2009'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Medical Treatment
100%
Bevacizumab
100%
Advanced Colorectal Cancer
100%
Epidermal Growth Factor Receptor
66%
Colorectal Cancer
50%
Medical Therapy
50%
Cetuximab
50%
Panitumumab
50%
Treatment Options
33%
Targeted Agents
33%
Clinical Practice
33%
Metastatic Colorectal Cancer (mCRC)
33%
Clinical Trials
16%
Chemotherapy
16%
High Risk
16%
Personalized Therapy
16%
Unselected Patients
16%
Clinical Benefit
16%
Patient Demographics
16%
Overall Survival
16%
Progression-free Survival
16%
KRAS mutation
16%
Tumor Progression
16%
Tumor Response
16%
Oncologic
16%
Treatment Decisions
16%
Oxaliplatin
16%
Cytotoxic Agents
16%
Trial Design
16%
Standard Medical Therapy
16%
Predictive Marker
16%
Time-related
16%
Patients with Colorectal Cancer
16%
Active Substances
16%
Therapy Options
16%
Irinotecan
16%
Treatment Algorithm
16%
Median Overall Survival
16%
Salvage Therapy
16%
Line of Therapy
16%
Novel Targeted Agents
16%
First-line Chemotherapy
16%
Active Agent
16%
BRAF mutation
16%
Practical Management
16%
Palliative Setting
16%
Later-line
16%
Practice Design
16%
Riches
16%
Medicine and Dentistry
Combination Therapy
100%
Colorectal Carcinoma
100%
Bevacizumab
75%
Epidermal Growth Factor Receptor Antibody
50%
Cetuximab
37%
Panitumumab
37%
Biological Marker
25%
Overall Survival
25%
Metastatic Colorectal Cancer
25%
Neoplasm
12%
Tumor Progression
12%
Personalized Medicine
12%
Patient Population
12%
Progression Free Survival
12%
Oxaliplatin
12%
Salvage Therapy
12%
Predictive Marker
12%
Irinotecan
12%
First-Line Chemotherapy
12%
Diseases
12%
Cytotoxic Agent
12%
Pharmacology, Toxicology and Pharmaceutical Science
Combination Therapy
100%
Colorectal Carcinoma
100%
Bevacizumab
75%
Epidermal Growth Factor Receptor Antibody
50%
Cetuximab
37%
Panitumumab
37%
Biological Marker
25%
Overall Survival
25%
Metastatic Colorectal Cancer
25%
Neoplasm
12%
Chemotherapy
12%
Progression Free Survival
12%
Tumor Growth
12%
Oxaliplatin
12%
Irinotecan
12%
First-Line Chemotherapy
12%
Diseases
12%
Cytotoxic Agent
12%